Innate Pharma SA logo

Innate Pharma SA - Class A

LTS:0EVI (France)   Class A
€ 2.25 (+3.57%) Apr 23
At Loss
P/B:
3.52
Market Cap:
€ 182.70M ($ 195.50M)
Enterprise V:
€ 130.14M ($ 139.25M)
Volume:
104.00
Avg Vol (2M):
1.67K
Also Trade In:
Volume:
104.00
At Loss

Business Description

Description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Name Current Vs Industry Vs History
Cash-To-Debt 2.32
Equity-to-Asset 0.28
Debt-to-Equity 0.77
Debt-to-EBITDA -21.69
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.87
Distress
Grey
Safe
Beneish M-Score -1.5
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.76
9-Day RSI 55.45
14-Day RSI 52.09
6-1 Month Momentum % -11.48
12-1 Month Momentum % -21.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.73
Quick Ratio 3.73
Cash Ratio 2.33
Days Sales Outstanding 173.19

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.8
Shareholder Yield % 1.39

Financials (Next Earnings Date:2024-09-12)

LTS:0EVI's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Innate Pharma SA Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 51.901
EPS (TTM) (€) -0.09
Beta 0.27
Volatility % 24.61
14-Day RSI 52.09
14-Day ATR (€) 0.037129
20-Day SMA (€) 2.231625
12-1 Month Momentum % -21.74
52-Week Range (€) 2.12 - 3.26
Shares Outstanding (Mil) 80.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Innate Pharma SA Filings

Filing Date Document Date Form
No Filing Data

Innate Pharma SA Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Innate Pharma SA Frequently Asked Questions

What is Innate Pharma SA(LTS:0EVI)'s stock price today?
The current price of LTS:0EVI is €2.25. The 52 week high of LTS:0EVI is €3.26 and 52 week low is €2.12.
When is next earnings date of Innate Pharma SA(LTS:0EVI)?
The next earnings date of Innate Pharma SA(LTS:0EVI) is 2024-09-12.
Does Innate Pharma SA(LTS:0EVI) pay dividends? If so, how much?
Innate Pharma SA(LTS:0EVI) does not pay dividend.

Press Release

Subject Date
No Press Release